Skip to main content
EJNMMI Radiopharmacy and Chemistry
EJNMMI Radiopharmacy and Chemistry Cover Image

Articles

33 result(s) within Volume 7 of EJNMMI Radiopharmacy and Chemistry

Page 1 of 1

  1. 111In[In]-BnDTPA-trastuzumab-NLS is a radiopharmaceutical with theranostic applications for imaging and Meitner-Auger electron (MAE) radioimmunotherapy (RIT) of HER2-positive breast cancer (BC). Nuclear localizat...

    Authors: Conrad Chan, Vanessa Prozzo, Sadaf Aghevlian and Raymond M. Reilly
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:33
    Content type: Research Article Published on:

  2. Sodium iodide symporter (NIS) imaging by positron emission tomography (PET) is gaining traction in nuclear medicine, with an increasing number of human studies being published using fluorine-18 radiolabelled t...

    Authors: Dmitry Soloviev, Piotr Dzien, Agata Mackintosh, Gaurav Malviya, Gavin Brown and David Lewis
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:32
    Content type: Methodology Published on:

  3. 161Tb is a radiolanthanide with the potential to replace 177Lu in targeted radionuclide therapy. 161Tb is produced via the neutron irradiation of [160Gd]Gd2O3 targets, and must be purified from 160Gd and the deca...

    Authors: Scott W. McNeil, Michiel Van de Voorde, Chengcheng Zhang, Maarten Ooms, François Bénard, Valery Radchenko and Hua Yang
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:31
    Content type: Research article Published on:

  4. [18F]Flurpiridaz is a promising novel cardiac PET imaging tracer formed by the radiolabeling of pyridaben derivative with fluorine-18. Clinical studies on [18F]Flurpiridaz are currently at the phase III level for...

    Authors: Kurtulus Eryilmaz and Benan Kilbas
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:30
    Content type: Research article Published on:

  5. Radiopharmaceuticals are considered as regular medicinal products and therefore the same regulations as for non-radioactive medicinal products apply. However, specific aspects should be considered due to the r...

    Authors: Eline L. Hooijman, Carolline M. Ntihabose, Thom G. A. Reuvers, Julie Nonnekens, Else A. Aalbersberg, Jordy R. J. P. van de Merbel, Judith E. Huijmans, Stijn L. W. Koolen, Jeroen J. M. A. Hendrikx and Erik de Blois
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:29
    Content type: Methodology Published on:

  6. Quantification of actinium-225 through gamma counter measurements, when there is no secular equilibrium between actinium-225 and its gamma emitting daughters bismuth-213 and/or francium-221, can provide valuab...

    Authors: Dayana Castillo Seoane, Marijke De Saint-Hubert, Stephen Ahenkorah, Clarita Saldarriaga Vargas, Maarten Ooms, Lara Struelens and Michel Koole
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:28
    Content type: Research article Published on:

  7. The radiometal gallium-68 (68Ga) is increasingly used in diagnostic positron emission tomography (PET), with 68Ga-labeled radiopharmaceuticals developed as potential higher-resolution imaging alternatives to trad...

    Authors: Bryce J. B. Nelson, Jan D. Andersson, Frank Wuest and Sarah Spreckelmeyer
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:27
    Content type: Review Published on:

  8. 2-[18F]Fluoroethyltosylate ([18F]FEtOTs) is a well-known 18F-fluoroalkylating agent widely used to synthesize radiotracers for positron emission tomography. The widespread use of [18F]FEtOTs is due in part to its...

    Authors: Martha Sahylí Ortega Pijeira, Sofia Nascimento dos Santos, Yasniel Babi Araujo, André Luis Lapolli, Marcio Nardelli Wandermuren, Zalua Rodríguez Riera, Ivone Carvalho, Philip H. Elsinga and Emerson Soares Bernardes
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:26
    Content type: Research article Published on:

  9. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Jun Toyohara, Mohammed Al-Qahtani, Ya-Yao Huang, Emiliano Cazzola, Sergio Todde, Shozo Furumoto, Renata Mikolajczak, Clemens Decristoforo, Nic Gillings, Min Yang, Raymond Reilly, Adriano Duatti, Antonia Denkova, Ralf Schirrmacher, Giuseppe Carlucci, Yann Seimbille…
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:25
    Content type: Review Published on:

  10. [177Lu]Lu-PSMA is used for the treatment of metastatic castration-resistant prostate cancer. For in-house productions, quality control methods are essential for ensuring product quality, and thus patient safety. ...

    Authors: Else A. Aalbersberg, Tammie T. Cao, Martine M. Geluk-Jonker and Jeroen J. M. A. Hendrikx
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:24
    Content type: Research article Published on:

  13. With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent y...

    Authors: Alexander W. E. Sadler, Leena Hogan, Benjamin Fraser and Louis M. Rendina
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:21
    Content type: Review Published on:

  14. The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [68Ga]Ga-FAPI-46 is a new radiotrace...

    Authors: Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao and Maaz Zuhayra
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:20
    Content type: Research article Published on:

  15. Myocardial perfusion imaging (MPI) is one of the most commonly performed investigations in nuclear medicine procedures. Due to the longer half-life of the emerging positron emitter copper-64 and its availabili...

    Authors: Norah AlHokbany, Ibrahim AlJammaz, Basem AlOtaibi, Yousif AlMalki, Bander AlJammaz and Subhani M. Okarvi
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:19
    Content type: Research article Published on:

  16. The development of radiopharmaceuticals requires extensive evaluation before they can be applied in a diagnostic or therapeutic setting in Nuclear Medicine. Chemical, radiochemical, and pharmaceutical paramete...

    Authors: Aruna Korde, Renata Mikolajczak, Petra Kolenc, Penelope Bouziotis, Hadis Westin, Mette Lauritzen, Michel Koole, Matthias Manfred Herth, Manuel Bardiès, Andre F. Martins, Antonio Paulo, Serge K. Lyashchenko, Sergio Todde, Sangram Nag, Efthimis Lamprou, Antero Abrunhosa…
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:18
    Content type: Review Published on:

  17. The efficient management of hospital radiopharmacy is very important for a good workflow in nuclear medicine and essential to ensure the correct traceability of the radiopharmaceuticals administered to patient...

    Authors: Jesús Luis Gómez Perales
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:17
    Content type: Research article Published on:

  18. Radionuclide therapy (RNT) has become a very important treatment modality for cancer nowadays. Comparing with other cancer treatment options, sufficient efficacy could be achieved in RNT with lower toxicity. β− e...

    Authors: Runze Wang, Bernard Ponsard, Hubert Wolterbeek and Antonia Denkova
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:16
    Content type: Research article Published on:

  19. Positron emission tomography (PET) is a powerful tool in medical imaging, especially in combination with the PET radionuclide fluorine-18 that possesses optimal characteristics. For labelling of biomolecules a...

    Authors: Carsten Sven Kramer, Luca Greiner, Klaus Kopka and Martin Schäfer
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:15
    Content type: Research article Published on:

  20. This review presents the results of a survey conducted by the International Atomic Energy Agency on cyclotrons and related infrastructure used for radionuclide and radiopharmaceutical production which are supp...

    Authors: Miguel A. Avila-Rodriguez, Amir R. Jalilian, Aruna Korde, David Schlyer, Mohammad Haji-Saeid, Jose Paez and Saul Perez-Pijuan
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:14
    Content type: Review Published on:

  21. Tissue hypoxia is a pathological condition characterized by reducing oxygen supply. Hypoxia is a hallmark of tumor environment and is commonly observed in many solid tumors. Non-invasive imaging techniques lik...

    Authors: Arian Pérez Nario, Jenilee Woodfield, Sofia Nascimento dos Santos, Cody Bergman, Melinda Wuest, Yasniel Babí Araújo, André Luis Lapolli, Frederick G. West, Frank Wuest and Emerson Soares Bernardes
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:13
    Content type: Research article Published on:

  22. Combining optical (fluorescence) imaging with nuclear imaging has the potential to offer a powerful tool in personal health care, where nuclear imaging offers in vivo functional whole-body visualization, and t...

    Authors: Anthony W. McDonagh, Brooke L. McNeil, Julie Rousseau, Ryan J. Roberts, Helen Merkens, Hua Yang, François Bénard and Caterina F. Ramogida
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:12
    Content type: Research article Published on:

  23. The increasing incidence of cancer over the years is one of the most challenging problems in healthcare. As cancer progresses, the recruitment of several immune cells is triggered. Infiltration of tumor-associ...

    Authors: Bruna Fernandes, Paula Kopschina Feltes, Carolina Luft, Luiza Reali Nazario, Cristina Maria Moriguchi Jeckel, Ines F. Antunes, Philip H. Elsinga and Erik F. J. de Vries
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:11
    Content type: Review Published on:

  24. Noninvasive molecular imaging using peptides and biomolecules labelled with positron emitters has become important for detection of cancer and other diseases with PET (positron emission tomography). The positr...

    Authors: Raphaël Hoareau, Tore Bach-Gansmo, Paul Cumming and Dag Erlend Olberg
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:10
    Content type: Research article Published on:

  25. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Emerson Bernardes, Peter Caravan, R. Michael van Dam, Winnie Deuther-Conrad, Beverley Ellis, Shozo Furumoto, Benjamin Guillet, Ya-Yao Huang, Hongmei Jia, Peter Laverman, Zijing Li, Zhaofei Liu, Filippo Lodi, Yubin Miao, Lars Perk, Ralf Schirrmacher…
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:9
    Content type: Review Published on:

  26. Recent advances in nanotechnology have offered new hope for cancer detection, prevention, and treatment. Nanomedicine, a term for the application of nanotechnology in medical and health fields, uses nanopartic...

    Authors: Martha Sahylí Ortega Pijeira, Herlys Viltres, Jan Kozempel, Michal Sakmár, Martin Vlk, Derya İlem-Özdemir, Meliha Ekinci, Seshasai Srinivasan, Amin Reza Rajabzadeh, Eduardo Ricci-Junior, Luciana Magalhães Rebelo Alencar, Mohammed Al Qahtani and Ralph Santos-Oliveira
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:8
    Content type: Review Published on:

  27. Prosthetic approach for the radiolabeling of biologics with fluorine-18 is a robust strategy and has been employed for many years. It requires fast, biocompatible and selective reactions suited to these fragil...

    Authors: Mylène Richard, Françoise Hinnen and Bertrand Kuhnast
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:7
    Content type: Research article Published on:

  28. The GMP-compliant production of radiopharmaceuticals has been performed using disposable units (cassettes) with a dedicated synthesis module. To expand this “plug ‘n’ synthesize” principle to a broader scope o...

    Authors: Jan Wenz, Felix Arndt and Samuel Samnick
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:6
    Content type: Methodology Published on:

  29. Flumazenil (FMZ) is a functionally silent imidazobenzodiazepine which binds to the benzodiazepine binding site of approximately 75% of the brain γ-aminobutyric acid-A receptors (GABAARs). Positron Emission Tomogr...

    Authors: Thibault Gendron, Gianluca Destro, Natan J. W. Straathof, Jeroen B. I. Sap, Florian Guibbal, Charles Vriamont, Claire Caygill, John R. Atack, Andrew J. Watkins, Christopher Marshall, Rebekka Hueting, Corentin Warnier, Véronique Gouverneur and Matthew Tredwell
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:5
    Content type: Research article Published on:

  30. Receptor-interacting protein 1 kinase (RIPK1) is a key enzyme in the regulation of cellular necroptosis. Recently, cyclohexyl (5-(2-acetamidobenzo[d]thiazol-6-yl)-2-methylpyridin-3-yl)carbamate (PK68, 5) has been...

    Authors: Tomoteru Yamasaki, Katsushi Kumata, Atsuto Hiraishi, Yiding Zhang, Hidekatsu Wakizaka, Yusuke Kurihara, Nobuki Nengaki and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:4
    Content type: Research article Published on:

  31. Pretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-...

    Authors: Hugo Helbert, Emily M. Ploeg, Douwe F. Samplonius, Simon N. Blok, Ines F. Antunes, Verena I. Böhmer, Gert Luurtsema, Rudi A. J. O. Dierckx, Ben L. Feringa, Philip H. Elsinga, Wiktor Szymanski and Wijnand Helfrich
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:3
    Content type: Research article Published on:

  32. The need for a stability evaluation of [18F]FDG is evident. The main purpose of this study was to make recommendations for determining the shelf life based on the available stability literature and our own two-ce...

    Authors: Jes G. Holler, Børge Renmælmo and Richard Fjellaksel
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:2
    Content type: Research article Published on:

EJNMMI Reports - Kindly explore our collections here

Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://link.springer.com/journal/41824/collections

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany


CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/

EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.


Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.

Submit manuscript

Follow

  • ISSN: 2365-421X (electronic)

Affiliated with

EANM'24 banner vertical